MDT-AP-3069
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 22.7
- sex
- M
- new_clusters
- S1
- umap1_2d
- -0.905469061
- umap2_2d
- -10.94564102
- umap1_3d
- -3.369471344
- umap2_3d
- -0.202441402
- umap3_3d
- 5.431086472
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.420
- E2F_TARGETS+0.400
- INTERFERON_GAMMA_RESPONSE+0.380
- G2M_CHECKPOINT+0.370
- MYC_TARGETS_V1+0.370
- ALLOGRAFT_REJECTION+0.350
- INFLAMMATORY_RESPONSE+0.340
- NOTCH_SIGNALING+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- ANDROGEN_RESPONSE+0.320
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.160
- HEME_METABOLISM-0.150
- KRAS_SIGNALING_DN-0.110
- HEDGEHOG_SIGNALING-0.090
- SPERMATOGENESIS-0.080
- APICAL_SURFACE-0.070
- MYOGENESIS-0.070
- ANGIOGENESIS-0.040
- PEROXISOME-0.010
- ADIPOGENESIS+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2865 | Med | Medulloblastoma | 0.908 |
| 2 | MDT-AP-0826 | Med | Medulloblastoma | 0.897 |
| 3 | MDT-AP-3324 | Med | Medulloblastoma | 0.871 |
| 4 | TCGA-E7-A97P-01A-11R-A38B-07 | — | — | 0.865 |
| 5 | BS_RD4D5F9F | Med | Medulloblastoma | 0.862 |
| 6 | MDT-AP-0731 | Med | Medulloblastoma | 0.859 |
| 7 | SRR934737 | — | — | 0.857 |
| 8 | TCGA-CN-4734-01A-01R-1436-07 | — | — | 0.855 |
| 9 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.853 |
| 10 | MDT-AP-3095 | Med | Medulloblastoma | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |